Patient characteristics at HIV-DLBCL diagnosis
| . | Patients . | Missing . |
|---|---|---|
| N | 40 | |
| Demographics | ||
| Age (y) | 50.0 (44.0-56.2) | 0 |
| Sex (male) | 35 (87.5) | 0 |
| HIV infection | ||
| Time since HIV diagnosis (y) | 16.0 (5.7-23.2) | 1 |
| AIDS stage | 14 (35.0) | 0 |
| Active HIV replication (>200 copies per mL) | 14 (35.0) | 0 |
| Ongoing cART | 35 (87.5) | 0 |
| Protease inhibitor | 20 (57.1) | 5 |
| Nucleoside inhibitor of reverse transcriptase | 9 (25.7) | 5 |
| Nonnucleoside inhibitor of reverse transcriptase | 8 (22.9) | 5 |
| Positive HCV serological test | 13 (34.2) | 2 |
| Replicative HBV (positive HBV DNA) | 1 (2.5) | 0 |
| Lymphoma | ||
| Performance status | 0 | |
| 0-1 | 25 (62.5) | |
| 2 | 11 (27.5) | |
| 3-4 | 4 (10.0) | |
| Elevated LDH | 20 (51.3) | 1 |
| Lymphoma stage | 0 | |
| I-II | 1 (10.0) | |
| III-IV | 36 (90.0) | |
| >1 extranodal site | 22 (56.4) | 1 |
| R-IPI score | 0 | |
| Very good | 2 (5.0) | |
| Good | 20 (50.0) | |
| Poor | 18 (45.0) | |
| Immunological phenotypes | ||
| Immunoglobulin | 1 | |
| IgG (g/L) | 14.9 (9.9-18.8) | |
| IgA (g/L) | 2.6 (1.7-3.3) | |
| IgM (g/L) | 1.0 (0.6-1.5) | |
| CD45+ leucocytes (× 109/L) | 1.12 (0.74-1.55) | 1 |
| T lymphocytes | 1 | |
| CD3+ T lymphocytes (× 109/L) | 0.89 (0.58-1.28) | |
| CD3+CD4+ T lymphocytes (× 109/L) | 0.27 (0.13-0.42) | |
| CD3+CD8+ T lymphocytes (× 109/L) | 0.55 (0.36-0.76) | |
| CD4+:CD8+ ratio | 0.4 (0.3-0.7) | |
| NK lymphocytes | 1 | |
| NK lymphocytes (× 109/L) | 0.09 (0.05-0.14) | |
| B lymphocytes | ||
| CD19+ B lymphocytes (× 109/L) | 0.07 (0.03-0.14) | 1 |
| CD19+CD27−IgD+ among B lymphocytes (%) | 74.0 (47.0-87.0) | 8 |
| CD19+CD27+IgD+ among B lymphocytes (%) | 5.5 (2.0-10.2) | 8 |
| CD19+CD27+IgD− among B lymphocytes (%) | 11.0 (4.8-21.5) | 8 |
| Cytokines | ||
| IL-6 blood level (pg/mL) | 14.7 (6.9-24.8) | 1 |
| IL-10 blood level (pg/mL) | 26.4 (13.6-54.7) | 0 |
| BAFF blood level (pg/mL) | 1012.8 (677.4-1690.1) | 2 |
| . | Patients . | Missing . |
|---|---|---|
| N | 40 | |
| Demographics | ||
| Age (y) | 50.0 (44.0-56.2) | 0 |
| Sex (male) | 35 (87.5) | 0 |
| HIV infection | ||
| Time since HIV diagnosis (y) | 16.0 (5.7-23.2) | 1 |
| AIDS stage | 14 (35.0) | 0 |
| Active HIV replication (>200 copies per mL) | 14 (35.0) | 0 |
| Ongoing cART | 35 (87.5) | 0 |
| Protease inhibitor | 20 (57.1) | 5 |
| Nucleoside inhibitor of reverse transcriptase | 9 (25.7) | 5 |
| Nonnucleoside inhibitor of reverse transcriptase | 8 (22.9) | 5 |
| Positive HCV serological test | 13 (34.2) | 2 |
| Replicative HBV (positive HBV DNA) | 1 (2.5) | 0 |
| Lymphoma | ||
| Performance status | 0 | |
| 0-1 | 25 (62.5) | |
| 2 | 11 (27.5) | |
| 3-4 | 4 (10.0) | |
| Elevated LDH | 20 (51.3) | 1 |
| Lymphoma stage | 0 | |
| I-II | 1 (10.0) | |
| III-IV | 36 (90.0) | |
| >1 extranodal site | 22 (56.4) | 1 |
| R-IPI score | 0 | |
| Very good | 2 (5.0) | |
| Good | 20 (50.0) | |
| Poor | 18 (45.0) | |
| Immunological phenotypes | ||
| Immunoglobulin | 1 | |
| IgG (g/L) | 14.9 (9.9-18.8) | |
| IgA (g/L) | 2.6 (1.7-3.3) | |
| IgM (g/L) | 1.0 (0.6-1.5) | |
| CD45+ leucocytes (× 109/L) | 1.12 (0.74-1.55) | 1 |
| T lymphocytes | 1 | |
| CD3+ T lymphocytes (× 109/L) | 0.89 (0.58-1.28) | |
| CD3+CD4+ T lymphocytes (× 109/L) | 0.27 (0.13-0.42) | |
| CD3+CD8+ T lymphocytes (× 109/L) | 0.55 (0.36-0.76) | |
| CD4+:CD8+ ratio | 0.4 (0.3-0.7) | |
| NK lymphocytes | 1 | |
| NK lymphocytes (× 109/L) | 0.09 (0.05-0.14) | |
| B lymphocytes | ||
| CD19+ B lymphocytes (× 109/L) | 0.07 (0.03-0.14) | 1 |
| CD19+CD27−IgD+ among B lymphocytes (%) | 74.0 (47.0-87.0) | 8 |
| CD19+CD27+IgD+ among B lymphocytes (%) | 5.5 (2.0-10.2) | 8 |
| CD19+CD27+IgD− among B lymphocytes (%) | 11.0 (4.8-21.5) | 8 |
| Cytokines | ||
| IL-6 blood level (pg/mL) | 14.7 (6.9-24.8) | 1 |
| IL-10 blood level (pg/mL) | 26.4 (13.6-54.7) | 0 |
| BAFF blood level (pg/mL) | 1012.8 (677.4-1690.1) | 2 |
The results are presented as n (%) for categorical variables and as median (IQR) for quantitative variables.
HBV, hepatitis B virus; HCV, hepatitis C virus; LDH, lactate dehydrogenase.